These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 26312959)
1. Triple dosing with high doses of buprenorphine: Withdrawal and plasma concentrations. Hvittfeldt E; Charlotte G; Fridolf I; Håkansson A J Opioid Manag; 2015; 11(4):319-24. PubMed ID: 26312959 [TBL] [Abstract][Full Text] [Related]
2. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Kuhlman JJ; Levine B; Johnson RE; Fudala PJ; Cone EJ Addiction; 1998 Apr; 93(4):549-59. PubMed ID: 9684393 [TBL] [Abstract][Full Text] [Related]
3. An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy. Caritis SN; Bastian JR; Zhang H; Kalluri H; English D; England M; Bobby S; Venkataramanan R Am J Obstet Gynecol; 2017 Oct; 217(4):459.e1-459.e6. PubMed ID: 28669739 [TBL] [Abstract][Full Text] [Related]
4. Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets. Simojoki K; Lillsunde P; Lintzeris N; Alho H Eur Addict Res; 2010; 16(2):85-90. PubMed ID: 20130408 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder. Haasen C; Linden M; Tiberg F J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599 [TBL] [Abstract][Full Text] [Related]
7. Hair analysis for long-term monitoring of buprenorphine intake in opiate withdrawal. Pirro V; Fusari I; Di Corcia D; Gerace E; De Vivo E; Salomone A; Vincenti M Ther Drug Monit; 2014 Dec; 36(6):796-807. PubMed ID: 24713865 [TBL] [Abstract][Full Text] [Related]
8. Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects. De S; Jain R; Ray R; Dhawan A; Varghese ST Indian J Physiol Pharmacol; 2008; 52(1):53-63. PubMed ID: 18831352 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study. Albayaty M; Linden M; Olsson H; Johnsson M; Strandgården K; Tiberg F Adv Ther; 2017 Feb; 34(2):560-575. PubMed ID: 28070862 [TBL] [Abstract][Full Text] [Related]
10. Single high-dose buprenorphine for opioid craving during withdrawal. Ahmadi J; Jahromi MS; Ghahremani D; London ED Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648 [TBL] [Abstract][Full Text] [Related]
11. Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens. Petry NM; Bickel WK; Badger GJ Addiction; 2001 Jun; 96(6):823-34. PubMed ID: 11399214 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Chiang CN; Hawks RL Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349 [TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Chawarski MC; Schottenfeld RS; O'Connor PG; Pakes J Drug Alcohol Depend; 1999 Jun; 55(1-2):157-63. PubMed ID: 10402160 [TBL] [Abstract][Full Text] [Related]
14. [Maintaining opioid abstinence long after inpatient treatment with opioid substitution in an addictology hospital unit]. Bouab O; Lahmek P; Meunier N; Aubin HJ; Michel L Rev Med Brux; 2013; 34(3):132-40. PubMed ID: 23951853 [TBL] [Abstract][Full Text] [Related]
15. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. Correia CJ; Walsh SL; Bigelow GE; Strain EC Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637 [TBL] [Abstract][Full Text] [Related]